|
Compass Therapeutics Inc (NASDAQ: CMPX) |
|
Compass Therapeutics Inc
CMPX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Compass Therapeutics Inc 's sales fell
in IV. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.61 %
Compass Therapeutics Inc net loss increased from $-13 millions, to $-15 millions in IV. Quarter 2024,
• More on CMPX's Growth
|
|
Compass Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 16.45 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 372.73.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.55.
• More on CMPX's Valuation
|
|
|
|
|
Compass Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 16.45 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 372.73.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.55.
Compass Therapeutics Inc Price to Book Ratio is at 2.53 lower than Industry Avg. of 1411.8. and higher than S&P 500 Avg. of 0.01
• More on CMPX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com